Page last updated: 2024-09-05

cp 100356 and dofequidar

cp 100356 has been researched along with dofequidar in 1 studies

Compound Research Comparison

Studies (cp 100356)	Trials (cp 100356)	Recent Studies (post-2010) (cp 100356)	Studies (dofequidar)	Trials (dofequidar)	Recent Studies (post-2010) (dofequidar)
8	0	3	40	2	5

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Guengerich, P; Kajiji, S; Kim, RB; Wandel, C; Wilkinson, GR; Wood, AJ	1

Other Studies

1 other study(ies) available for cp 100356 and dofequidar

Article	Year
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer research, 1999, Aug-15, Volume: 59, Issue:16 Topics: Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Digoxin; Down-Regulation; Enzyme Inhibitors; Humans; Oxidoreductases, N-Demethylating; Substrate Specificity	1999

Article

Year

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.

Cancer research, 1999, Aug-15, Volume: 59, Issue:16

Topics: Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Digoxin; Down-Regulation; Enzyme Inhibitors; Humans; Oxidoreductases, N-Demethylating; Substrate Specificity

1999